Friday 6 December 2019 ,
Friday 6 December 2019 ,
Latest News
  • Deferment of Khaleda's bail petition hearing unprecedented: BNP
  • No change in post of AL president in next council: Quader
  • India vet rape and murder: Police shoot dead 4 suspects
  • Nation divided on Hyderabad encounter
  • Cinematographer Mahfuzur Rahman dies
  • Uber had 6,000 US sexual assault reports in 2 years
  • Modi, Pranab, Sonia likely to attend Bangabandhu’s birth centenary celebrations, says Foreign Minister AK Abdul Momen
1 September, 2018 00:00 00 AM
Print

Drug slows brain shrinkage in progressive MS

Drug slows 
brain shrinkage 
in progressive MS

A drug that has long been used in Japan for asthma may slow down brain shrinkage in people with progressive multiple sclerosis, a preliminary trial has found. The study, published Aug. 30 in the New England Journal of Medicine, tested an oral drug called ibudilast. It is not approved in the United States, but has been used for years in Japan as a treatment for asthma and for vertigo in stroke survivors.

Researchers found that the drug slowed brain shrinkage by 48 per cent when compared with an inactive placebo among patients with progressive MS.

Multiple sclerosis is a neurological disorder caused by a misguided immune system attack on the protective sheath around nerve fibers in the spine and brain. Depending on where the damage occurs, symptoms include vision problems, muscle weakness, numbness, and difficulty with balance and coordination.

Most people with MS are initially diagnosed with the "relapsing-remitting" form, meaning that their symptoms flare up for a time and then ease.

Patients in this trial had progressive MS, where the disease steadily worsens without periods of recovery.

And while more than a dozen drugs are available to manage relapsing MS, there are few options for progressive forms of the disease, said Dr. Robert Fox, lead researcher on the new study.

In general, the drugs for relapsing MS do not work for people with progressive forms, said Fox, a neurologist at the Cleveland Clinic.

The biology of progressive MS, Fox explained, seems to be "fundamentally different." Inflammation drives relapsing MS, while the progressive forms seem to be driven by degeneration of nerve cells in the brain, following damage from the inflammatory phase.

Ibudilast can suppress inflammation, and it was first tested against relapsing MS -- where it failed to prevent relapses. But, Fox said, the drug did slow brain shrinkage (atrophy). And that led researchers to suspect it might help patients with progressive MS.

Fox and his colleagues recruited 255 patients with progressive MS from 28 US medical centers. Patients were randomly assigned to take either ibudilast or placebo pills every day for 96 weeks.

In the end, patients on the drug showed, on average, 48 per cent less atrophy in their brain tissue.

The big question, Fox said, is whether that will slow patients' progression to disability.

"This is a proof-of-concept," he said. "We've shown that this slows brain atrophy. We haven't shown that it slows clinical progression."

Longer-term studies are needed to prove that. For now, Fox stressed, "this drug is not available in the US, and it will be some time before it is."

Bruce Bebo is executive vice president of research for the National Multiple Sclerosis Society -- which partly funded the trial.

Bebo called the findings a "milestone," but cautioned that the drug will have to show benefits against the disease's course, and not only brain shrinkage.

"Those clinical benefits take a longer time to measure," he said. For patients and families, though, this is one more positive step against progressive MS, he added.

"This is one of a number of trials testing new therapies for progressive MS," Bebo said. "It's only a matter of time before we'll have more and better treatments."

                                                                        

HealthDay

 

Comments

More Op-ed stories
Creating atmosphere for sustainable sanitation practice to reach SDGs Globally, around 1 billion people lack access to safe water and 2.4 billion people lack access to improved sanitation. Bangladesh, with a population of 150 million, has made significant progress towards…

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting